Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis update.

William T Mayr1, Moses Rodriguez

  • 1Department of Neurology, Mayo Clinic Rochester, USA.

Minnesota Medicine
|July 3, 2002
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a central nervous system autoimmune disease. Current treatments for acute relapses are effective, but disease-modifying therapies offer only modest benefits in reducing attacks and have less impact on disability progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Telomere length as a marker of biological age in paediatric multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis.

Annals of neurology·2025
Same author

Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.

Neurology·2025
Same author

Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.

Journal of child neurology·2025
Same author

Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.

Neurology·2025
Same journal

Parent's hesitance about HPV Vaccine: Using the CASE approach to address their concerns.

Minnesota medicine·2021
Same journal

Vaping, lung injury, and mental health Minnesota 2018-2019.

Minnesota medicine·2021
Same journal

Characteristics of clinical extrapulmonary nontuberculous mycobacteria isolates in Minnesota, 2013-2017.

Minnesota medicine·2020
Same journal

Challenges for younger adults with diabetes.

Minnesota medicine·2020
Same journal

Telemedicine in Minnesota: A look at how four specialties are using it.

Minnesota medicine·2019
Same journal

The Doctor Will See You On Screen: Telemedicine offers convenient access to care, cost savings and the same quality as in-person visits-sometimes.

Minnesota medicine·2019
See all related articles

Area of Science:

  • Neurology
  • Immunology
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability in young adults in Europe and North America.
  • MS is characterized by dysfunction in the central nervous system over time, with likely autoimmune etiology involving genetic and environmental factors.

Purpose of the Study:

  • To summarize the key aspects of multiple sclerosis, including its symptoms, disease progression, diagnostic methods, and current treatment strategies.
  • To review the efficacy of treatments for acute relapses and the impact of disease-modifying therapies on MS course.

Main Methods:

  • Review of existing literature on multiple sclerosis.
  • Summary of diagnostic criteria and imaging techniques (MRI, CSF studies).
  • Analysis of treatment outcomes for acute relapses and long-term management.

Related Experiment Videos

Main Results:

  • Methylprednisolone is the primary treatment for acute MS relapses; plasma exchange is an alternative for refractory cases.
  • Preventive immunomodulatory treatments reduce MS attack frequency by approximately 30%.
  • Evidence for disease-modifying therapies altering disability progression in MS is less convincing.

Conclusions:

  • MS diagnosis remains clinical, supported by MRI and CSF findings.
  • While treatments for acute relapses are established, the long-term benefits of immunomodulatory therapies on disability progression require further investigation.
  • Ongoing research focuses on improving preventive strategies for multiple sclerosis.